Psychosis Treatment
Psychosis Treatment - Related Videos
05:52
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
0 Views •
Cited by 34 •
2013
Handwriting analysis software significantly improves upon existing instruments measuring movement disorders. Individuals at risk for psychosis and healthy controls completed handwriting tasks to test for dyskinesia. Results suggest that youth at risk for psychosis exhibit dyskinesia and that handwriting analysis could significantly contribute to wider dissemination of early identification...
01:26
Psychosis: Goals of Pharmacotherapy
0 Views •
2024
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28
Psychosis and Antipsychotic Drugs: Overview
0 Views •
2024
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:27
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
0 Views •
2024
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered. Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
07:30
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
0 Views •
Cited by 3 •
2020
This is a 3T magnetic resonance imaging study aiming to investigate grey matter volume differences between cannabis-induced psychosis patients and non-psychotic chronic cannabis users.
FAQs
Dopamine D2 receptor blockade is a central pharmacologic mechanism for reducing psychotic symptoms, while activity at serotonin 5-HT2A receptors distinguishes many second-generation agents from medicines acting mainly through dopamine pathways. These receptor effects matter clinically because they may influence both symptom improvement and the pattern of adverse effects considered during treatment selection.
Effective symptom control does not eliminate the need to consider adverse effects. Movement disorders, sedation, and metabolic changes can alter the overall benefit-risk balance of a medicine, so pharmacologic decisions require attention to both therapeutic goals and tolerability. This balance supports safer prescribing and helps align treatment with an individual’s medical circumstances.
Antipsychotic medicines do not necessarily produce identical clinical profiles because their receptor effects can differ. Dopamine D2 blockade remains an important shared pharmacologic mechanism, whereas many second-generation agents also affect serotonin 5-HT2A receptors. Relating these mechanisms to symptom response and adverse-event profiles helps pharmacology guide comparisons among available treatment approaches.
Selection incorporates symptom severity, medical history, potential interactions, and adherence. These factors help clinicians weigh expected benefits against risks rather than treating medication choice as a one-size-fits-all decision. Considering them together supports individualized care, safer prescribing, and a treatment plan that is more compatible with the person’s clinical situation.
Adherence is an important part of treatment planning because a medicine’s potential benefit depends on its continued use within the clinical plan. Pharmacology therefore considers adherence alongside symptom severity, medical history, and interactions. Giving this factor explicit attention can support individualized care and contribute to relapse prevention as treatment progresses.
Pharmacology contributes to relapse prevention by supporting sustained management of psychotic symptoms and by encouraging treatment choices that balance benefit with tolerability. Considering adherence, medical history, interactions, and adverse-event risks helps make treatment safer and more individualized. These principles connect medication selection with longer-term functioning rather than focusing only on immediate symptom reduction.
Pharmacology research examines how treatment can reduce distress while limiting adverse effects such as movement disorders, sedation, and metabolic changes. Studying dopamine and serotonin receptor actions, along with factors affecting medication selection, supports safer prescribing and more individualized care. This work also provides a basis for developing treatments that act in more targeted ways.